Molecular Validation of PACE4 as a Target in Prostate Cancer.

ABSTRACT: Prostate cancer remains the single most prevalent cancer in men. Standard therapies are still limited and include androgen ablation that initially causes tumor regression. However, tumor cells eventually relapse and develop into a hormone-refractory prostate cancer. One of the current challenges in this disease is to define new therapeutic targets, which have been virtually unchanged in the past 30 years. Recent studies have suggested that the family of enzymes known as the proprotein convertases (PCs) is involved in various types of cancers and their progression. The present study examined PC expression in prostate cancer and validates one PC, namely PACE4, as a target. The evidence includes the observed high expression of PACE4 in all different clinical stages of human prostate tumor tis

SUBMITTER: D'Anjou F 

PROVIDER: S-EPMC3104696 | biostudies-literature | 2011 Jun

REPOSITORIES: biostudies-literature